New drug BRY812 targets Hard-to-Treat gynecologic cancers in early trial
NCT ID NCT07311538
First seen Jan 09, 2026 · Last updated May 05, 2026 · Updated 21 times
Summary
This study tests a new drug called BRY812 in people with advanced gynecologic cancers (ovarian, endometrial, or ovarian clear cell) that have a specific marker called LIV-1. The goal is to see if the drug can shrink tumors. About 56 participants will receive the drug, and researchers will monitor safety and how well it works. This is an early-stage trial, so the main focus is finding the right dose and checking for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GYNECOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.